Quantcast

Latest Grunenthal GMBH Stories

2014-03-03 16:25:58

REDWOOD CITY, Calif., March 3, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013. "AcelRx made strong progress in 2013 with the successful completion of the Zalviso(TM) (sufentanil sublingual NanoTab system) Phase 3 program, the...

Thalidomide Apology From German Drug Maker
2012-09-02 07:04:50

redOrbit Staff & Wire Reports - Your Universe Online The German company that developed a drug which resulted in thousands of congenital birth defects in the 1950s and 1960s issued their first ever apology on Friday, but those impacted by the medication's side-effects say that the statement was too long in coming and fell short of making amends for the harm caused. The drug in question, a sedative known as thalidomide that was marketed as a treatment for morning sickness in pregnant...

2011-03-22 07:06:00

PRINCETON, N.J., March 22, 2011 /PRNewswire/ -- Nectid, Inc. (www.nectid.com) announced today that it has completed the sale of a number of patents and patents-applications to Grunenthal GmbH (www.grunenthal.com), a European specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes a number of novel chemical entities from Nectid's Pain Drug Discovery program and two key drug delivery platforms (www.nectid.com/pipeline_newdrug)....

2011-02-09 06:48:00

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (OTC Bulletin Board: PRTT) announced today that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market. Ram Sesha, Protect's Chief Operating Officer, said, "We are very happy to see...

2010-10-13 08:42:00

- National Marketing Authorizations Expected in Due Course/Marketing Partner Grunenthal Preparing to Launch in Multiple European Markets Late Next Year - LAVAL, QC, Oct. 13 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced its twice-daily tramadol-acetaminophen has received a positive opinion under the European Union Decentralized Procedure in eight countries (Czech Republic, Iceland, Ireland, Poland, Portugal, Slovakia, Slovenia and Spain). Marketing...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'